Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M

Emmaus Life Sciences, Inc.

2026-Q1 EPS reported -$0.05 revenue$1,982,000

Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.
Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.
MENA segment sales surged 446%, partially offsetting U.S. decline.
Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.